Creating hope for all facing illness.
Looking back on what our company has accomplished so far and what Mitsubishi Tanabe Pharma should be like in the future society, we newly formulated “MISSION” and “VISION 30”

**MISSION** | Creating hope for all facing illness.

**VISION 30** | Be a healthcare company that delivers optimal therapy to each individual.
Break Through the Boundaries of Pharmaceuticals by Realizing “SHINKA”

Mitsubishi Tanabe Pharma Group newly established MISSION, “Creating hope for all facing illness.” on April 1, 2021. We have set the corporate vision as VISION 30 “Be a healthcare company that delivers optimal therapy to each individual,” and we are making progress to realize MISSION and VISION 30.

Under our new Medium-Term Management Plan 21-25, we focus on “precision medicine” to realize “Providing appropriate medical care to appropriate patients at appropriate timing.” In addition, we contribute to improving the quality of life of patients and their families by providing “Around the pill solutions” from prevention to prognosis, centered on our therapeutic drugs. Then, establishing new customer contact points, collecting and analyzing healthcare data, we take on the challenge of expanding business opportunities. In order to achieve these goals, we will more actively promote open innovation with the world’s best partners based on our drug discovery capabilities. Moreover, as a Mitsubishi Chemical Holdings Corporation group company, we will make extensive use of intra-group collaboration to create synergies.

The Group’s origins date back to 1678 when the Tanabeya Medicine shop began manufacturing and selling medicines in Osaka. For over three centuries, our mission has grown to using the Group’s global value chain and linking with the resources and strengths of our partners to provide treatments and healthcare services to people around the world, and to earn the trust of patients and their families, medical professionals, and society to achieve sustainable growth for our business.

The Mitsubishi Tanabe Pharma Group will deepen and evolve our drug discovery capabilities in order to deliver true value to the society, by always seeking to identify what the patients and their families truly need, and we call it “SHINKA.” In response to environmental changes, we will keep on challenging to provide “SHINKA.” Please look forward to the future of Mitsubishi Tanabe Pharma Group.

Table of Contents

Prologue | MISSION, VISION 30 / Message from the President / Table of Contents 01
Connecting History 03
Chapter 01 Connecting to the Future | Management Plan 05
Chapter 02 Connecting Our Strengths | Research & Development 11
Business Activities / Value Chain 13
Global Development 15
Chapter 03 Connecting to Hope | Amyotrophic Lateral Sclerosis (ALS) 17
Thoughts on Patient Groups 19
Developer Insight 21

About the Company
Learn More about Mitsubishi Tanabe Pharma 22
Introducing the Mitsubishi Chemical Holdings Group 22
Sustainability 25
Main Products and Health Support Website 27
Corporate Website, Historical Museum, Tanamin 29
Over 300 Years of Fighting Disease and Drug Discovery

Mitsubishi Tanabe Pharma has been providing medicines and treatments to patients for over 300 years. TANABEYA Gohei originally established Tanabe Seiyaku in 1678 in Tosabori, Osaka, as a family business to produce and sell its proprietary Tanabeya Infusing Medicine. Two centuries later, the 12th generation TANABE Gohei guided the company through the turbulent war periods and vastly expanded its customer base by adding Western medicines to the company’s specialties.

Our history is built on creating hope for all facing illness for which no treatments were available, such as tuberculosis, the lifestyle diseases of hypertension and diabetes, rheumatoid arthritis, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). We seek not just to eliminate the incurable, but to eliminate the lack of choice in treatments.
The mission of all of our employees:
Creating hope for all facing illness.
MISSION and Medium-Term Management Plan 21-25

Imagine the future. Change for tomorrow.

The Mitsubishi Tanabe Pharma Group is looking deep into itself to identify its true value and its place in the society of the future. As society evolves, advances in digitalization, online medical care, gene therapy, and other areas are leading us to a new era where patients’ hopes go beyond conventional “medicine.” This is a fundamental change, and must have a clear understanding of the true value that we as a Group can provide.

KAITEKI Value for Tomorrow

Imagine the future. Change for tomorrow.

Imagine our future. How do we get there to a sustainable future?

KAITEKI — the sustainable well-being of people, society and our planet Earth.

For our future, the Mitsubishi Chemical Holdings Corporation (MCHC) Group will bring solutions for tomorrow.

Mission and VISION 30 for Realizing KAITEKI

As the core company responsible for the MCHC Group’s healthcare business (PHARMACEUTICAL AND HEALTH), Mitsubishi Tanabe Pharma will contribute to the MCHC Group’s Vision “Realizing KAITEKI”.

MISSION

Creating hope for all facing illness.

VISION 30

Be a healthcare company that delivers optimal therapy to each individual.

Providing Value to Society

We provide therapeutic agents and wide-ranging solutions designed with the patient and their family in mind.

- We provide highly effective treatment to specific patient groups and increase patient satisfaction with detailed analysis of the disease.
- We provide solutions focused on prevention, pre-symptomatic disease care, prevention of aggravation and prognosis.
- We continue improving the value of our therapeutics and solutions by collecting and analyzing healthcare data.

What is KAITEKI?

KAITEKI means “the sustainable well-being of people, society and our planet Earth.” It is an original concept of the MCHC Group that propose a way forward in the sustainable development of society and the planet, in addition to serving as a guide for solving environmental and social issues.

Click here to learn more about KAITEKI

Lay the foundation for growth strategies during the transformation period toward VISION 30

Research & development
Realize precision medicine focused on central nervous system and immuno-inflammation treatments. Focused on vaccines area and contribute to preventive medicine.

Business development
Strengthen business in the US and Japan, and develop around the pill solutions to create new customer contact points.

Management base
Create a resilient organization and optimize the allocation of management resources for achieving VISION 30.

Develop precision medicine and around the pill solutions that will provide the new value called for in our VISION 30. Provide appropriate medical care to appropriate patients at appropriate timing.

Early diagnosis support solution
Patients can quickly access the most effective medical care and slow the disease progression.

Focused on prevention, pre-symptomatic disease care, prevention of aggravation and prognosis, we provide Around the pill solutions.

Treatment support solution
Treatment is smooth with reduced medical burden in a patient’s daily life.
Growth strategies for VISION 30

We have set our corporate image for the year 2030 in our VISION 30 to “Be a healthcare company that delivers optimal therapy to each individual.” Here, we introduce two of the key areas for realizing our vision: “precision medicine” and “around the pill solutions.”

**Precision Medicine**

Mitsubishi Tanabe Pharma defines precision medicine as “provide appropriate medical care to appropriate patients at appropriate times.” There is a great variety of patients around the world, but they often are given few options for treatments that meet their personal needs. When the option doesn’t provide what a patient requires, the patient has “unmet medical needs,” of which there are many.

We will analyze the information in the data to identify patient groups to create effective treatments and preventive methods and provide medical care that would be the most beneficial for patients. We are conducting research unremittingly so that we can provide new treatment options for all people who are facing illness.

Mitsubishi Tanabe Pharma Precision Medicine

- Genetic biomarkers

**Message**

The drug discovery begins here by approaching the medical condition scientifically and asking “what kind of treatment can we provide to what kind of patient?”

OKUYAMA Masahiro
Vice President, Head of Research Unit/Neuroscience Sohyaku, Innovative Research Division

The Neuroscience Research Unit researches the central nervous system to discover candidates for new drugs, and improve the value of developing drugs and approved drugs.

Discovering new drug candidates involves recognizing common pathologies for intractable neurological diseases, such as ALS, and then seeking to identify the cause and researching treatments. We took a major step in this direction with the establishment of the Neuro Discovery Lab in Boston of the United States in April 2021. We also actively collaborate with academias and research institutions in research that provides patient samples with clinical information and integrate knowledge.

For me, precision medicine means providing treatments that patients feel are highly effective. People who work at pharmaceuticals companies get the most happiness when they can contribute to helping a patient enjoy living a normal life and can see the smiles of the patient’s family.

Drug discovery derived from causative genes is expected strong potential because it addresses the root of disease. Nevertheless, even patients with the same causative gene have diverse pathologies and progressions. Understanding one phenomenon is not enough, we also need to reveal them by the science of patient physiology and genetics. Drug discovery begins by asking “what kind of treatment can we provide to what kind of patient?”
Around the Pill Solutions

Mitsubishi Tanabe Pharma’s around the pill solutions are intend to help improve the quality of life of patients and their families through the different phases in patient journey and expand the value of current treatments.

As a pharmaceuticals company, we have encountered all sorts of diseases that have given us a wide range of knowledge, experience and expertise. We know a drug alone cannot be an end-to-end solution for all the challenges patients and their families are facing in their lives. By taking a holistic approach, we strive to accelerate digital innovations in our communities so that patients know that “Mitsubishi Tanabe Pharma has this disease covered.”

The potential impact of around the pill solutions

- Mitsubishi Tanabe Pharma’s around the pill solutions have the potential to shorten time to diagnosis to offer more therapeutic opportunities, and to provide better medication support system to be focused on improving the quality of life of patients and their families.
- Broader external collaborations on solutions will lead to developing new products and services beyond the scope of the company.
- New clinical insights based on data obtained from the solutions have the potential to improves the value of existing drugs and inform the development of future therapies as a way to giving back to society.

Around the Pill Solutions in ALS

ALS is not only a fast-progressing severe disease, but also one that takes over a year to fully diagnose. Finding ways to provide patients and their families an earlier diagnosis is an important social mission we take very seriously. Our around the pill solutions, particularly using innovative healthcare information technologies, aim to address this unmet medical need in ALS care.

In addition to the rapid evolution of digital technology, the spread of the coronavirus has created an ever-increasing need for remote symptom monitoring, while patients are at home. As a leading company providing treatments and around the pill solutions for ALS patients, we remain committed to continued innovation and dedicated to creating a better ALS community.

Examples of Around the Pill Solutions in ALS

Early diagnosis
In 2019, we began evaluating new digital solutions for remote symptom monitoring that has the potential to detect changes in ALS progression using smartphones, mobile apps and wearable devices. We are working collaboratively with clinicians, digital health specialists and patient communities in the United States to determine facility of using digital technology to enable early diagnosis of ALS and to create a platform between patients and healthcare providers.

Digital medication management
Our digital medication platform aims to connect patients to the support they need, prevent dosing errors, and keep them engaged and on track with their treatment. We are creating a new web-portal and a dedicated mobile application to provide family members and caregivers with unlimited access to prescription information and medication approval status.
In the near future, medical needs in society are expected to continue extending beyond treatment to fully encompass prevention and prognosis. To continue meeting the social need, the pharmaceuticals industry will have to integrate digital technologies into their organizations and implement digital transformation (DX). Mitsubishi Tanabe Pharma is aggressively advancing DX initiatives to construct a digital infrastructure, train professional specialists, and invest in strategic digital technology.

We are particularly focused on DX of our R&D operations. One area we are beginning to apply digital technologies is the analysis of laboratory test values, where we are using it in sensing technology to better capture hard-to-detect “movement,” functional evaluations of walking and other functions associated with intractable neurological diseases, simultaneous multi-layered analysis using AI, and identification of causative genes of diseases—all of which is opening new doors for new drug discovery.

How will healthcare be different in the future? Personalized medicine, such as precision medicine, is a major trend. The increasing ability to obtain data about a person’s genes and living conditions is making it possible to design treatments catered for a specific individual. DX is the driving force behind these developments.

Our growth strategies for precision medicine and around pill solutions are on the forefront of this trend. Providing precision medicine starts with connecting with patients and getting to know them deeply. Then, as we develop the optimal treatment for the patient, we integrate around the pill solutions using digital technologies that go beyond the medicine itself to maximize the therapeutic effect and respond to the patient’s unique issues.

At the same time, we will implement “ambidextrous DX” by using automation and online technology to make all of our business operations more efficient and all of our existing businesses more robust.

Our world is changing dramatically, but with DX and all of our employees are advancing the Company’s new MISSION and VISION 30, we are creating the next generation of healthcare.
Real workstyle reform that creates new value

**Workstyle Reform Strategies**

- **Raise digital literacy**
  - Apply digital technology to improve work efficiency and increase the productivity of each employee

- **Working styles that lead to the growth of employees and the Company**
  - Take advantage new work styles unbound by time and place to provide new opportunities for independent learning that will deepen expertise and spur innovation

- **Foster common values**
  - Accepting diverse values and changing working styles, cultivate shared values through penetration of our MISSION and VISION 30

We will use digital technology and new work styles unconstrained by time or location to create a healthy environment where employees can work with a sense of satisfaction and shared values so our employees and the Company are highly engaged and working together for mutual growth.

**Office Environment for a New Way of Working**

We are taking the initiative to establish satellite work bases and telework infrastructure to accommodate work styles in the era of the “new normal.” We moved the Tokyo head office in August 2021 to the Palace Building, which houses Mitsubishi Chemical Holdings. With workspaces equipped to support high-performance work and designed to accommodate individual work styles, the new offices will provide a healthy environment where employees can work with a sense of satisfaction.

**Respecting Diversity**

Diversity and inclusion is a management strategy, and respect for employee health and diversity is a designated point of materiality for the Company. One specific measure in this area was the revision to our rules of employment in 2020 to recognize common-law marriage and same-sex partners as spouses. We will continue to acknowledge differences and encourage each person’s individual strengths as an essential element to maximizing our business performance.
Numerous diseases still do not have effective treatments or medicines. Mitsubishi Tanabe Pharma is constantly working to discover and create new drugs to fulfill the unmet medical needs of all people facing illness.
Realize precision medicine focused on central nervous system and immuno-inflammation treatments
Focus on vaccines area and contribute to preventive medicine.

Major development pipeline

<table>
<thead>
<tr>
<th>Research Area</th>
<th>Late-stage Development Projects (Indication)</th>
<th>Summary / Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central nervous system</td>
<td><strong>MT-1186</strong> (ALS)</td>
<td>Under development as a Radicava oral suspension agent. Oral ingestion facilitates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>easier administration than conventional intravenous infusion. Suspension agent is</td>
</tr>
<tr>
<td></td>
<td></td>
<td>easy to ingest even for patients with difficulty swallowing.</td>
</tr>
<tr>
<td></td>
<td><strong>ND0612</strong> (Parkinson’s disease)</td>
<td>Under development by Israeli subsidiary NeuroDerm along with a pump-type drug</td>
</tr>
<tr>
<td></td>
<td></td>
<td>administration device to provide 24-hour subcutaneous injection for blood</td>
</tr>
<tr>
<td></td>
<td></td>
<td>concentration stability.</td>
</tr>
<tr>
<td>Immuno-inflammation</td>
<td><strong>MT-7117</strong> (Erythropoietic protoporphyria (EPP), systemic sclerosis, etc.)</td>
<td>Under development as the world’s first oral treatment for EPP, which is</td>
</tr>
<tr>
<td></td>
<td></td>
<td>characterized by sensitivity to sun exposure. Clinical trials started in 2021 to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>expand indications for systemic sclerosis, which causes fibrosis of skin and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>internal organs.</td>
</tr>
<tr>
<td></td>
<td><strong>MT-0551</strong> (IgG4-related disease)</td>
<td>Biopharmaceutical introduced by an overseas company and under development in Japan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>as an immuno-inflammation indication for chronic IgG4-related disease. Released</td>
</tr>
<tr>
<td></td>
<td></td>
<td>for sale in Japan in 2021 as a central nervous system indication for neuromyelitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>optica spectrum disorder.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>aiming to commercialization in Canada in 2021.</td>
</tr>
<tr>
<td></td>
<td><strong>MT-2355</strong> (5 combined vaccine)</td>
<td>Under development in Japan as a combined vaccine adding Hib infection vaccine to the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4 combined vaccine. Combined vaccines reduce the number of immunization shots to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>one, improving convenience for children, caretakers, and medical institutions.</td>
</tr>
</tbody>
</table>

Developing a New Modality for COVID-19 Vaccines

Canadian subsidiary Medicago has successfully produced and is conducting clinical trials of virus-like particle (VLP) vaccine (MT-2766) for COVID-19. The company plans to release the vaccine aiming to commercialization in Canada in 2021.

A VLP has a similar external surface as a virus and is expected to have a high immune-acquisition effect (efficacy) when adopted for vaccines. VLP vaccines have been attracting much attention in recent years for being extremely safe new type of vaccine modality. VLP vaccines, unlike real viruses, do not have genetic information and can therefore be administered without concern of the virus multiplying in the body. Medicago has unique technology to efficiently extract and purify VLPs produced inside plant cells. The technology is also very promising for its potential to reduce both costs and production time.

Virus-like particles

VLP structure (Outer surface)  
Virus structure (Genetic material inside)  
Production facility at Medicago
Business processes for creating new value

To “Be a healthcare company that delivers optimal therapy to each individual,” we will create new value by linking all of our business activities to deliver therapeutic drugs as well as a wide variety of solutions.

**Sohyaku. Innovative Research Division**

The Sohyaku division mainly engages in drug discovery research to develop new drug candidates to advance to clinical trials. Ongoing research centered on central nervous system and immuno-inflammatory diseases is aimed at creating the precision medicine that the Company is developing to drive its long-term business growth.

The division’s objectives are to promote open innovation using external drug discovery resources, increase the Company’s options for the future by developing new modalities and strengthening our presence in new fields, and building out our portfolio in focused therapeutic areas.

**Ikuyaku. Integrated Value Development Division**

The Ikuyaku division links the development, medical, and data science functions and the overseas subsidiaries into a single team to bring out the full potential of our products and product evidence construction. We also seek to deliver optimal medical care to patients through activities ranging from clinical and database research to discovery of new evidence and raising disease awareness. The division also seeks to provide therapeutic drug around the pill solutions for patients, their families, and healthcare professionals.
The SC Division works to enhance the competitiveness of the Company’s research technology for chemistry, manufacturing, and controls (CMC)*2 through comprehensive planning, promotion, and management of pharmaceutical process research, pharmaceutical and packaging research, analytical research, and CMC regulatory compliance.

As a company specializing in manufacturing, we have the technological foundation and a global supply chain system to ensure stable supply and delivery of high-quality pharmaceutical products to patients around the world.

*2 Comprehensive research that supports pharmaceutical manufacturing and quality.

The SC Division works to enhance the competitiveness of the Company’s research technology for chemistry, manufacturing, and controls (CMC)\textsuperscript{*2} through comprehensive planning, promotion, and management of pharmaceutical process research, pharmaceutical and packaging research, analytical research, and CMC regulatory compliance.

As a company specializing in manufacturing, we have the technological foundation and a global supply chain system to ensure stable supply and delivery of high-quality pharmaceutical products to patients around the world.

*2 Comprehensive research that supports pharmaceutical manufacturing and quality.

Production Technology & Supply Chain Management (SC) Division

The SC Division works to enhance the competitiveness of the Company’s research technology for chemistry, manufacturing, and controls (CMC)\textsuperscript{*2} through comprehensive planning, promotion, and management of pharmaceutical process research, pharmaceutical and packaging research, analytical research, and CMC regulatory compliance.

As a company specializing in manufacturing, we have the technological foundation and a global supply chain system to ensure stable supply and delivery of high-quality pharmaceutical products to patients around the world.

*2 Comprehensive research that supports pharmaceutical manufacturing and quality.

Production Technology & Supply Chain Management (SC) Division

The SC Division works to enhance the competitiveness of the Company’s research technology for chemistry, manufacturing, and controls (CMC)\textsuperscript{*2} through comprehensive planning, promotion, and management of pharmaceutical process research, pharmaceutical and packaging research, analytical research, and CMC regulatory compliance.

As a company specializing in manufacturing, we have the technological foundation and a global supply chain system to ensure stable supply and delivery of high-quality pharmaceutical products to patients around the world.

*2 Comprehensive research that supports pharmaceutical manufacturing and quality.

Sales and Marketing Division

The Sales and Marketing Division provides healthcare professionals with highly specialized information on pharmaceuticals and community healthcare so patients can receive optimal medical care. Key to these activities are our medical representatives (MRs).

We use big data from our sales operations in Japan to provide new information and services related to pharmaceutical products at the right time and through the most appropriate channels. Our aim is to be a healthcare company in close touch with community healthcare.

Sales and Marketing Division

The Sales and Marketing Division provides healthcare professionals with highly specialized information on pharmaceuticals and community healthcare so patients can receive optimal medical care. Key to these activities are our medical representatives (MRs).

We use big data from our sales operations in Japan to provide new information and services related to pharmaceutical products at the right time and through the most appropriate channels. Our aim is to be a healthcare company in close touch with community healthcare.
Global business activities supporting the health of people worldwide

Mitsubishi Tanabe Pharma is a leading pharmaceutical company in Japan. From its head office in the “medicine town” of Dosho-machi, Osaka, Mitsubishi Tanabe Pharma conducts integrated global operations at about 20 business sites overseas spanning Asia, Europe, and North America.

**Domestic**

**Business Activities in Japan**

Healthcare professionals need accurate information about the drugs to provide the best medical care to their patients. Medical representatives (MRs) are at the center of these activities, and Mitsubishi Tanabe Pharma currently has some 1,500 MRs at 13 branch offices across the country actively responding to and delivering information about our pharmaceutical products. In addition, our Medical Information Center directly responds to inquiries and supports patients and healthcare professionals by providing information about our more than 300 types of pharmaceuticals.

**Research and manufacturing sites**

Mitsubishi Tanabe Pharma has two research sites for new drugs in Japan—the Yokohama Office and the Shonan Office, both in Kanagawa Prefecture. Shonan Health Innovation Park (Shonan iPark), which took over duties as the Shonan Office in May 2019, is home to pharmaceutical companies, drug discovery ventures, IT companies, and others that have come together to increase the opportunities for synergies and open innovation.

Our two pharmaceuticals manufacturing sites are the Yoshitomi Plant in Fukuoka Prefecture and the Onoda Plant in Yamaguchi Prefecture, which are subsidiaries of Mitsubishi Tanabe Pharma Factory Ltd. These manufacturing plants manufacture the majority of the Company’s pharmaceutical products and implement strict quality control systems. The Kashima Office in Osaka Prefecture, where we have been conducting research on pharmaceutical CMC technology, will be shut down in December 2021 and consolidated into the Onoda Plant as a CMC base for new modalities.
Overseas, MRs provide information and sell pharmaceutical products through local subsidiaries in North America, Europe, and Asia. In the United States in 2017, the Company released its Radicava ALS treatment agent, which is its core ethical drug offering outside of Japan. Radicava is becoming widely accepted as a new treatment option and is currently used by over 5,000 ALS patients in the United States.

We also operate several subsidiaries in Europe and Asia that are marketing our products in their local regions. In Europe, companies in the United Kingdom and Germany handle drug products for cardiovascular system and other indications in the European market. In Asia, Mitsubishi Tanabe Pharma’s pre-merger entity operated fully established businesses in Taiwan and Indonesia. Since the merger, the company’s business has continued gradually expanding and it currently operates nine companies in seven countries including Singapore and several other ASEAN countries. We will continue expanding our product offerings in overseas market and seeking to maximize product value while developing business activities that help raise the quality of life of patients and their families.

**Ethical drug sales**

Overseas, Mitsubishi Tanabe Pharma is carrying out distinctive research centered at its subsidiaries overseas. Canada’s Medicago Inc. is presently developing a COVID-19 vaccine using its unique technology for producing vaccines using plant-based virus-like particles (VLPs). In central nervous system treatments, the Israeli firm NeuroDerm Ltd. is developing an innovative drug-device combinations for Parkinson’s disease. In addition, in the United States, where venture companies and researchers from all over the world gather, we are represented by the antibody research firm Tanabe Research Laboratories U.S.A., Inc. and the Neuro Discovery Lab, which searches for drug targets related to the central nervous system. Working in close collaboration with Japanese researchers, these subsidiaries are conducting cutting-edge drug discovery research.

Our overseas operations follow each countries guidelines for ethical drugs, and we have strict standards for compliance in all areas from the manufacturing process to package content. The Production Technology & Supply Chain Management Division leads tightly integrated operations between our four plants overseas and two plants in Japan and is constructing a robust global supply system to ensure we continue providing a reliable supply of high-quality pharmaceuticals meeting the specific standards in each region.
Connecting to Hope

Advances in healthcare have brought unprecedented health and longevity to mankind. Nevertheless, many people continue to battle disease.

We would like everyone to know about the incurable disease known as ALS, amyotrophic lateral sclerosis. The Ice Bucket Challenge that was popular in 2014 increased ALS awareness, and we hope the information here will also help spread understanding of the disease and help patients and their families live better lives.

Our objective is to contribute the health of people around the world. Create a system for all of society to help battle incurable diseases by providing information and raise awareness. Through nonstop research, develop and provide treatment methods and drugs as quickly as possible. Provide hope for the future by battling against diseases that could potentially afflict anyone.
What is ALS?

ALS, or amyotrophic lateral sclerosis, is a progressive disease that affects motor nerve cells and causes the body to gradually lose the ability to move. The cause of ALS is not completely understood, and it remains a disease that is considered to be incurable.

As ALS progresses, brain signals fail to reach the muscles, causing them to weaken. The initial symptoms of the disease vary but can be broadly divided into two types. One is difficulty moving the limbs, making it hard to hold heavy objects or move the legs forward. The other is difficulty moving the mouth, which often causes slurred speech or a nasal voice. The symptoms gradually spread throughout the body, making it difficult for a patient to walk, eat, and even breathe on their own. In addition, trouble swallowing food makes it difficult to obtain the necessary nutrition. ALS does not affect the senses of sight, hearing, or touch, and although they are unable to make their body move the way they want it to, people with ALS are fully alert and conscious.

Most people who develop ALS are in their 50s to 70s, and there are estimated to be about 10,000 ALS patients in Japan. Every patient is different, but the disease tends to progress rapidly, and the average life expectancy after onset is generally three to five years. Longer-term treatment is currently available through the use of respiratory equipment, intravenous feeding, and gastrostomy feeding. Patients often find it difficult to talk when they are using respiratory equipment, and alternative ways have been devised to enable other means of communicating.

ALS remains incurable, however, progress toward a cure is advancing every day in genitive research and the development of regenerative medicine and medical devices. Identifying and properly treating the symptoms early is critical because treatment begun early is now able to slow the progression of the disease. However, screening and diagnosis is often late because the range of symptoms of ALS make it difficult to distinguish from other diseases and because the relatively few number of cases have led to low general awareness of ALS. Right now, increasing public awareness and understanding is one of the best ways to fight ALS.

We invite you to visit our ALS Station “Connecting to Tomorrow, Connecting to People” website (Japanese language only) where we provide information about ALS pathology, treatments, related knowledge, and support systems aimed at raising awareness and understanding about ALS.

ALS and dysphagia diet

Patients with ALS lose weight for a variety of reasons. The weight loss greatly affects their medical condition, so proper nutritional management from the beginning is essential. As the symptoms progress, patients begin to have difficulty swallowing, called dysphagia, making it hard to eat and drink. Consuming food is critical to controlling the weight loss, and the special “dysphagia diet” helps patients eat by softening and changing the shape of food to make it easy to swallow.

The ALS Station “Connecting to Tomorrow, Connecting to People” website contains a wide range of information about ALS in an easy-to-understand format, including information about ALS pathology, treatments, related knowledge, and support systems. Click here to go to the ALS Station website (Japanese language only)

https://als-station.jp/
A little strength from each person makes a powerful group

ALS has long been viewed as a tragic illness with an image of patients staring at the ceiling with no hope of recovery. However, ALS patients are fully conscious and aware. With proper support, patients can continue to be active even as the disease progresses. Patients are not alone, there is a steadily expanding community of support.

ALS upends daily lives, and patients need ongoing medical care as well as long-term care, nursing, and welfare support. These create a substantial financial burden for patients, who need support not just from their families but from their communities as well. Support systems are gradually improving, but many patients are still without adequate support and are living in difficult circumstances.

The Japan ALS Association is an organization working to help patients with these circumstances. The association brings people together into a supportive community centered on patients and their families with the aim of creating a society where ALS patients can live with peace of mind.

The association was created in response to the moving book by KAWAGUCHI Takehisa about his battle with ALS. When Kawaguchi, who was the association’s first chairman, wrote his book, very little was known about ALS. People with ALS were socially isolated because the cause of the disease was unknown, and many thought it could be contagious. Since there was no treatment, doctors did not tell patients what the disease was. Kawaguchi’s description of his experience brought together patients and their caretakers across the country. Communication is vital for all ALS patients, and the ability to share their thoughts and have people they
can rely on is a hugely reassuring. Volunteers formed an association to work together to promote a correct understanding of the disease and the need to support patients.

With the help of patients and others, the association worked to improve the system for medical support and greatly enhanced the quality of life of patients and their caregivers. Particular progress has been made in creating systems for home healthcare. The association provides a broad range of support, including easing the financial burden by lending otherwise expensive respirators and communication devices, and successfully petitioning the government to include procedures like mucus suction that caregivers are allowed to provide with in-home services. The association is active in many areas, including seeking to persuade the government to increase the budget for ALS research and support. The association established the ALS Fund and is working with research institutes, universities, and pharmaceutical companies to promote development of treatment methods.

Finding a cure

ALS research and support has made large strides in recent years. New medical equipment, portable respirators, and computers with eye-tracking technology are helping patients live more enjoyable and meaningful lives. Nevertheless, the level of medical and long-term care varies greatly across regions. These differences are not limited to patients with ALS, they also exist for other diseases and modern social issues, such as aging populations. As such, pursuing solutions for ALS will also help address wider social issues. The Japan ALS Association is seeking to establish equal care to patients nationwide, creating employment opportunities for ALS patients, and engaging in various activities to connect with hope until a cure is found for ALS.

General awareness and understanding of ALS are still insufficient. The association is using its status as a nationwide organization to raise awareness by various means, including disseminating information about ALS and supporting counseling between ALS patients and healthcare workers. The association continues to grow by joining in meetings with patients and their families and recruiting patron members who provide financial support.

The Japan ALS Association website
(Japanese-language only)

The Japan ALS Association
(Japanese-language only)

http://alsjapan.org/

Japan ALS Association

The Japan Amyotrophic Lateral Sclerosis Association was established as a non-profit organization in 1986 and became a general incorporated association in 2012. With the goal of realizing a society where ALS patients can live with full dignity as human beings, the association seeks to “battle together and walk together with ALS patients” by investigating the cause of ALS, promoting treatment research, and improving the medical treatment conditions for patients. Association members are primarily patients, their families, and people who have lost family to ALS, and also includes many people in the medical, healthcare, and welfare fields as well as researchers and the general public. The members are a community with ALS patients playing active roles in a wide variety of activities aimed at creating an inclusive society. The Japan ALS Association is a member organization of the International Alliance of ALS/MND Associations and participates in medical symposiums and other events promoting international exchange of information about ALS.
Hope for one patient is hope for all patients
“ALS treatments from Japan to the world”

In 2015, Japan approved a new ALS treatment that uses an intravenous drip to suppress the progression of ALS. The new treatment was much anticipated by patients around the world, who for the past 20 years had been limited to only a single treatment option. A project is currently under way to develop the treatment created in Japan for use worldwide.

Takei Koji
Vice President, Head of Global Product Strategy Department

When our ALS treatment was approved in Japan, I was in the United States. Developing treatments for ALS is extremely difficult, as evidenced by the lack of new drugs for about 20 years. ALS treatments are needed all over the world, so when I heard that the application for approval was successful in Japan, I knew that we had to seek approval in the United States.

Selling a treatment overseas requires approval from each country you want to sell it in. The United States is the world’s largest market for pharmaceuticals, and receiving approval there will have a major influence on the ability to sell the treatment in other countries.

ALS treatment for patients around the world

When our ALS treatment was approved in Japan, I was in the United States. Developing treatments for ALS is extremely difficult, as evidenced by the lack of new drugs for about 20 years. ALS treatments are needed all over the world, so when I heard that the application for approval was successful in Japan, I knew that we had to seek approval in the United States.

Selling a treatment overseas requires approval from each country you want to sell it in. The United States is the world’s largest market for pharmaceuticals, and receiving approval there will have a major influence on the ability to sell the treatment in other countries.
Our biggest concern when we were applying to the U.S. Food and Drug Administration (FDA) for approval was that the subjects of the clinical trial data were all Japanese patients. Applications overseas usually require clinical trial data obtained in that country or region. However, starting clinical trials in the United States from the very beginning would take too much time, so we organized all the data from Japanese researchers and from past clinical trials on stroke treatments in Japan and Europe into a coherent story that we hoped would convince the FDA. Analyzing a huge amount of data was a daunting task, and there were many obstacles due to differences in thinking between Japan and the United States. Nevertheless, we completed the task because we were strongly determined to get this medicine to patients.

In the end, the FDA gave us a high assessment for our materials and did not require any additional clinical trials. Supported by the expectations of patients and others, the FDA approved the treatment in May 2017, which was exceptionally fast.

A better treatment for everyone around the world

While we were submitting our application to the FDA, I realized that we needed to quickly develop an oral treatment. Radicava is administered via intravenous drip, but the convenience of an oral drug could really improve the quality of life of patients. Drugs that are injected or taken orally are usually very different, but we compiled many years of research data that showed it was possible to convert treatments into oral drugs. It’s not easy, of course, but we owed it to the patients to try. Beside the team developing the injectable treatment, we set up a dedicated team to focus on creating an oral treatment; and we told them to work as quickly as possible. Thanks to the efforts of R&D members in Japan and the United States, and the cooperation of patients and doctors, the development of the oral drug reached the final stages of clinical trials in 2020, and we are aiming to apply for approval as soon as possible.

Still, we have only just begun. We will continue working not just to slow the progression of ALS, but until we find a cure. We are continuing to do everything we can to develop better therapeutic agents.
KAITEKI Value for Tomorrow

As a member of the MCHC Group

We are a major operating company of the Mitsubishi Chemical Holdings Corporation (MCHC) Group, one of the world’s leading comprehensive chemical companies. Through the MCHC Group’s three business domains, Performance Products, Industrial Materials, and Health Care, the MCHC Group offers a wide range of solutions, based on the values of sustainability, health, and comfort.

MCHC Group Business Domains

Performance Products
We contribute toward a sustainable society by providing differentiated, high-performance solutions utilizing the Group’s wide range of products and technologies.

Industrial Materials
Our products and technologies support a variety of industries and societies. We are proceeding with the diversification of raw materials, including renewable resources and strengthening our business structures.

Health Care
Capitalizing on the Group’s comprehensive capabilities and network, we develop businesses for pharmaceuticals, active pharmaceutical ingredients and intermediates, pharmaceutical formulation materials, and advanced medication.

Maximizing Group Synergies

Three key synergies

The MCHC Group has established a solid foundation to develop and execute strategies to maximize Group synergies in the Health Care field. The Group maintains a Synergy Creation Committee and has an examination process for Group-wide strategic planning and decision-making based on the three perspectives of corporate, business, and digital transformation.

Corporate Synergy
- Legal functions, governance, internal control
- OAH* functions, overseas governance
- Each corporate function

Business Synergy
- Regenerative medicine
- Sales coordination
- Next-generation themes
- R&D collaboration
- Healthcare + medical materials

DX Synergy
- Carrying knowledge forward (digitizing the knowledge of veteran employees)
- Building a digital platform
- DX human resource

*OAH: Overseas Administrative Headquarters
The MCHC Group takes a multidimensional approach to innovation. For current and adjacent technology and business areas, the wide-ranging R&D efforts of our four main Business Companies take the lead. We increasingly leverage synergies between multiple MCHC Group companies to create value.
Sustainability activities

Under the concept of KAITEKI, the Group is pursuing businesses that solve a wide range of environmental and social issues. By providing value to society through our business and contributing to the realization of a sustainable society, we seek to continuously raise our corporate value. We define the important issues that the Group should address as our issues of materiality.

<table>
<thead>
<tr>
<th>Material issues*</th>
<th>Related SDGs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovative pharmaceuticals and healthcare services</td>
<td>9, 10, 13, 16, 17, 17</td>
</tr>
<tr>
<td>Quality assurance and stable supply</td>
<td>9, 10, 13, 16, 17, 17</td>
</tr>
<tr>
<td>Appropriate use of products</td>
<td>9, 10, 13, 16, 17, 17</td>
</tr>
<tr>
<td>Access to healthcare</td>
<td>9, 10, 13, 16, 17, 17</td>
</tr>
<tr>
<td>Stakeholder engagement</td>
<td>9, 10, 13, 16, 17, 17</td>
</tr>
<tr>
<td>Employee health, diversity and inclusion</td>
<td>9, 10, 13, 16, 17, 17</td>
</tr>
<tr>
<td>Environment-friendly business</td>
<td>9, 10, 13, 16, 17, 17</td>
</tr>
<tr>
<td>Ethics, fairness and integrity</td>
<td>9, 10, 13, 16, 17, 17</td>
</tr>
</tbody>
</table>

*Revised in fiscal 2021

Environmental issues

Group management is prioritizing initiatives related to climate change and other environmental issues. The Medium-Term Environmental Action Plan 21-25 adopted in fiscal 2020 outlines specific measures for environmental activities. The Group has also set reduction targets for greenhouse gas emissions for 2030 and 2050 with the aim of achieving zero emissions by 2050.

Specific initiatives under way are the installation of solar power generation facilities and other renewable energy equipment at our domestic bases. Steps to address environmental issues at our production and research sites include setting in-house standards that are stricter than legal standards and thorough measures to prevent air and water pollution.
Improving access to healthcare

Many people around the world cannot obtain necessary medicines and medical services due to inadequate healthcare systems, poverty, or disasters. Mitsubishi Tanabe Pharma endorses the objectives and contributes to the Global Health Innovative Technology Fund (GHIT Fund) and supports medical treatment research by making its pharmaceutical compound library available to research institutions focusing on malaria and neglected tropical diseases.

In addition, a Group company marketing ALS treatments in the United States operates the Searchlight Support program offering individualized treatment management assistance and insurance reimbursements for people being treated for ALS.

Contributions to medical care and welfare

In addition to developing new drugs for incurable diseases, we believe supporting patients and their families is also an important part of our mission. In fiscal 2012, we launched the Mitsubishi Tanabe Pharma Tenohira Partner Program to assist groups of people with incurable disease and their support groups with efforts to help patients recuperate, attend classes, obtain work, and raise their quality of life.

Our employees participate in the Table for Two program, which donates money for school lunches in developing countries, and a program for donating unwanted books, CDs, and DVDs to be sold for funds that are then used to provide vaccinations for children in developing countries.

Support activities for intractable disease patient organizations

Click here for information about the Mitsubishi Tanabe Pharma Tenohira Partner Program (Japanese language only)

https://www.mt-pharma.co.jp/sustainability/support.html

Health and productivity management/
Promoting diversity

The MTPC* Group Health Policy provides guidelines for activities to promote employee health. The Group began prohibiting smoking inside the company in fiscal 2017 and has introduced a health-promotion program that uses information and communications technology. We also have an e-learning program for all Group employees in Japan designed to help prevent and identify early signs of mental health issues.

Diversity is an integral part of our management strategy at the Group and encompasses both diversity and inclusion, which we define as having a diverse workforce and acknowledging, respecting, and using each person’s unique attributes. Mitsubishi Tanabe Pharma has received the highest ranking from the government under the accreditation system based on the Act on Promoting Women in the Workplace. We continue to step up our activities promoting diversity, including providing e-learning for managers of domestic Group companies to promote effective diversity management.

Contributions to medical care and welfare

In addition to developing new drugs for incurable diseases, we believe supporting patients and their families is also an important part of our mission. In fiscal 2012, we launched the Mitsubishi Tanabe Pharma Tenohira Partner Program to assist groups of people with incurable disease and their support groups with efforts to help patients recuperate, attend classes, obtain work, and raise their quality of life.

* Mitsubishi Tanabe Pharma Corporation

Corporate Governance

Compliance promotion structure

The Group provides compliance training at all Group companies with the aim of develop a high sense of ethics and moral standards among employees. Group companies overseas also provide compliance education and all companies have chief compliance officers.

We also take steps to prevent harassment in the workplace by raising awareness through companywide compliance training, new employee education, and the Company’s harassment prevention guidebook. We have also set up consultation counters for harassment issues, which offer privacy protection through anonymous consultation and reports.
Ethical Drugs

Ethical drugs are provided to patients by prescription under a doctor’s diagnosis. We contribute to improving the quality of life of patients and their families around the world by providing unique drugs focused on four therapeutic areas.

Domestic

Central nervous system

Products include Lexapro, a therapeutic agent for depression, and Radicut, a cerebral neuroprotective agent for acute-stage cerebral infarction and ALS indications.

Immuno-inflammation

Products include several biopharmaceuticals, Remicade, Symponi, and Stelara for rheumatoid arthritis, ulcerative colitis, psoriasis, and other indications, and the world’s first oral multiple sclerosis treatment, Imusera.

Vaccines

We market vaccines developed and manufactured by the Research Foundation for Microbial Diseases of Osaka University. Products include influenza vaccines and combined vaccines for children.

Other diseases

Diabetes and kidney

Products include two treatments for diabetes discovered by us, Tenelia, Canaglu, a combination drug Canalia, and a renal anemia treatment Vafseo.

Allergy

Products include therapeutic agents Rupafin for allergic disorders, such as allergic rhinitis and dermatosis.

Overseas

Central nervous system

We sell ethical drugs in Asia, Europe, and North America. In 2017, Radicava became the first new drug approved for ALS in the United States in nearly 20 years.
OTC Products

Over-the-counter (OTC) drugs are drugs that can be purchased by the general public at pharmacies and drugstores. We promote proper patient use and self-medication by selling OTC drugs and providing accurate drug information in Japan.

Flucort f, Cort f Series
Topical drug that suppresses inflammation and treats dermatitis and rashes. The Cort f series provides excellent anti-inflammatory effects suppressing redness, swelling, itching, and other symptoms and preventing irritation caused by scratching.

Tanabe ichoyaku urso, Urso Ukon
A gastrointestinal preparation that acts on the liver and is effective against fat intake induced stomach upset and indigestion. It improves stomach upset caused by fat intake by acting on the liver to promote biliary acid secretion.

Aspara Drinkα
A drink preparation containing potassium and magnesium aspartate and providing excellent effects for fatigue recovery. Easy to drink and with a refreshing flavor.

Talion AR
A rhinitis treatment for allergies with excellent effects on nasal congestion and runny nose caused by pollen. Containing the same composition as ethical drugs, quick absorption in the body produces rapid effects.

Patients and families
Health support website

Mitsubishi Tanabe Pharma also hosts more than 10 sites with information about various diseases and discussions about illnesses. Each site provides easy-to-understand information about disease symptoms and treatment methods along with other useful information that can be helpful for patients and their families.
We invite you to learn more about Mitsubishi Tanabe Pharma at our corporate website and the Mitsubishi Tanabe Pharma Historical Museum.

**Corporate website features**

The Mitsubishi Tanabe Pharma corporate website provides the latest information to its stakeholders. The corporate website presents news and basic information about the company and our R&D and sustainability activities. The site also has an easy-to-use portal page for patients and their families and medical professionals along with links to support sites dedicated to specific diseases.

**Historical museum**

The Mitsubishi Tanabe Pharma Historical Museum on the second floor of the Mitsubishi Tanabe Pharma headquarters in Osaka offers a colorful introduction to the history of the company since its founding in 1678 and the history and culture of Doshomachi, Osaka’s historical “medicine town.” The museum also has corners with 3D imaging and touch panels for learning about how the body works and how medicine heals diseases. In 2021, the museum introduced online virtual tours with video and audio of its main exhibits accessible at the time and place of the viewer’s convenience.
<table>
<thead>
<tr>
<th>Corporate character</th>
<th>Tanamin</th>
</tr>
</thead>
</table>

**Gender**: Unknown

**Habitat**: Hug Forest (Connected to Doshomachi by a secret path)

**Personality**: Easy-going and relaxed with a strong sense of justice

**Likes**: Hugging, lullabies, sleeping

**Favorite foods**: Herbs, spices

**Vocal call**: “Gyuu” (Sound to Tanamin’s hug)

---

**Tanamin** is a fairy with big blue hands covered in fluffy white fur. With those big hands, it envelops everyone it meets with a big hug. Its embrace is so comforting that people hugged by Tanamin fall asleep in its arms. When they awake, they feel refreshed and recovered. Tanamin takes life at a leisurely pace and may fall asleep with the people it hugs. Even though it is sleepy looking, Tanamin watches over Doshomachi with its big eyes and ears, finds tasty medicinal plants, and protects people’s health.

---

**Gyuu!**

Want to learn more about the company and Tanamin.

https://www.mt-pharma.co.jp/e/company/tanamin.html